What is the main purpose of this 8-K filing?

This Form 8-K filing is to report a material event: Boston Scientific Corporation's execution of an Agreement and Plan of Merger with EndoChoice Holdings, Inc., signaling a pending acquisition.

When is the acquisition of EndoChoice expected to close?

The closing of the merger transaction is expected to occur in the fourth quarter of 2016, subject to customary closing conditions.

What action should investors take regarding this announcement?

Investors are urged to carefully read the tender offer statement on Schedule TO and EndoChoice's solicitation/recommendation statement on Schedule 14D-9, which will be filed with the SEC. These documents will provide important details about the transaction. Free copies will be available on the SEC website.

Does this filing include financial details of the acquisition?

No, this specific 8-K filing does not contain detailed financial terms of the acquisition. It primarily announces the execution of the merger agreement. Further financial details will likely be disclosed in subsequent filings related to the tender offer.

BSX 8-K SEC Disclosure — Sep 27, 2016

Summary

Boston Scientific Corporation (BSX) has announced its entry into an Agreement and Plan of Merger with EndoChoice Holdings, Inc., effective September 27, 2016. This filing is a notification of this significant corporate event. The acquisition is structured as a merger, with a wholly-owned subsidiary of Boston Scientific to merge with EndoChoice. The transaction is subject to customary closing conditions and is anticipated to conclude in the fourth quarter of 2016. This move signals Boston Scientific's strategic intent to expand its business through acquisition, likely to bolster its product portfolio and market presence in the medical device sector. Investors should monitor future filings for details on the tender offer and any associated financial implications.

Key Highlights

1Boston Scientific Corporation has entered into an Agreement and Plan of Merger with EndoChoice Holdings, Inc.
2The transaction is expected to be completed in the fourth quarter of 2016.
3A wholly-owned subsidiary of Boston Scientific will merge with EndoChoice.
4The filing serves as notification of the merger agreement and associated tender offer process.
5Investors are advised to review forthcoming tender offer statements and related documents for detailed information.
6The acquisition is subject to customary closing conditions.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Sep 27, 2016)

Summary

Key Highlights

Frequently Asked Questions